AU Patent

AU2014218385B2 — Bilayer tablet formulations

Assigned to AstraZeneca UK Ltd · Expires 2016-02-25 · 10y expired

What this patent protects

Abstract The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The tablet can optional…

USPTO Abstract

Abstract The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The tablet can optionally comprise saxagliptin. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations.

Drugs covered by this patent

Patent Metadata

Patent number
AU2014218385B2
Jurisdiction
AU
Classification
—
Expires
2016-02-25
Drug substance claim
No
Drug product claim
No
Assignee
AstraZeneca UK Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.